GW Pharmaceuticals plc (GWPH) is a biopharmaceutical company focused on developing plant-derived cannabinoid therapeutics. The company has 1 marketed cannabinoid prescription drug Sativex and a deep pipeline of additional cannabinoid product candidates.Sativex, which consists of a formulated extract of the cannabis sativa plant, is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside of United States. It is not approved in the U.S. yet. Epidiolex, a liquid formulation of pure plant-derived cannabidiol, or CBD, is the company’s lead cannabinoid product candidate. It is under phase III testing in Dravet syndrome, Lennox-Gastaut syndrome, or LGS, and Tuberous Sclerosis. A phase III trial of the compound in infantile spasms is expected to start in Q4, 2016.Shares of GWPH have gained more than 18% year-to-date, and trade around $81.80.